Autoimmune diseases fact sheet. Office on Women's Health website. Available at: http://www.womenshealth.gov/publications/our-publications/fact-sheet/autoimmune-diseases.html. Updated July 16, 2012. Accessed June 24, 2016.
Biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis. EBSCO DynaMed website. Available at: http://www.ebscohost.com/dynamed. Updated July 9, 2014. Accessed July 18, 2014.
Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med. 2008; 148.
Efalizumab (marketed as Raptiva) information. US Food and Drug Administration website. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm133337.htm. Updated July 10, 2015. Accessed June 24, 2016.
Keystone EC, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2004;50(2):353-63.
Moderate to severe psoriasis: biologic drugs. National Psoriasis Foundation Web site. Available at: http://www.psoriasis.org/sublearn03_severe_biologics. Accessed June 24, 2016.
National drug code directory. US Food and Drug Administration website. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ucm142438.htm. Updated April 22, 2016. Accessed June 24, 2016.